Despite the challenges posed by the ongoing COVID-19 pandemic, the Asia Pacific interventional oncology device market will see strong growth through 2028 driven by a large and rapidly expanding patient pool, improving access to treatment, and the entry of new competitors. However, a lack of reimbursement and pricing pressures will continue to remain a challenge.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in the Asia Pacific region across a 10-year period.
The emergence of COVID-19 will affect the interventional oncology device market in the short term.
How will COVID-19 affect procedure volumes?
What will be the impact on market dynamics?
Physicians in the Asia Pacific region are looking for various minimally invasive interventional oncology devices to treat liver, kidney, and lung cancers, and many new interventional oncology companies and products are entering the market.
What are the major demographic, economic, and local trend differences across the Asia Pacific region that impact the adoption of and demand for these devices?
What technologies are available, and which products are set to be launched in the different countries going forward?
Reimbursement will be an important factor in the adoption of interventional oncology procedures in the Asia Pacific region.
What is the reimbursement scenario in the different Asia Pacific countries?
How will reimbursement impact the interventional oncology market?
Microwave ablation devices are growing in popularity among interventional oncologists.
What factors are driving the uptake of each of the ablation device types across the Asia Pacific countries?
How does the uptake of microwave ablation devices affect other types of ablation devices, like RF ablation devices, and how are competitors preparing for this shift?
- Interventional Oncology Devices - Market Insights - Asia Pacific
Author(s): Pankhil Gandhi, PharmD
Pankhil Gandhi is a research associate within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in transcatheter embolization and occlusion devices and deep venous disease treatment devices markets. Pankhil holds a Doctor of Pharmacy degree from the Babasaheb Ambedkar Marathwada University, Aurangabad.